A Multi-Center, Prospective Observational Study to Investigate the Safety, Compliance, and Efficacy of Omethyl QTlet Soft Capsule

• Published in: Journal of clinical medicine Vol. 11; no. 23; p. 6949
• Main Authors: Ki, You-Jeong, Han, Sang-Jin, Cha, Tae-Joon, Lee, Jae Hyuk, Seo, Eui Kyo, Yang, Jae Won, Hwang, Won Min, Jin, Dong Kyu, Park, Joo-Hyun, Ryu, Han Young, Park, Chang Gyu, Lee, Jun Hong, Choi, Si Wan, Cho, Eun Jeong, Kim, Weon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.11.2022; MDPI
• Subjects: Cardiovascular disease; Cholesterol; Clinical medicine; Drug dosages; Fatty acids; High density lipoprotein; Hypertension; hypertriglyceridemia; Lipids; Lipoproteins; Medicine; Metabolic disorders; Observational studies; omega-3 fatty acids; Omethyl QTlet soft capsule; Patients; Questionnaires; hypertriglyceridemia; Omethyl QTlet soft capsule; omega-3 fatty acids
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11236949

Omega-3 fatty acids have been shown to be effective in lowering triglyceride (TG) levels; however, tolerability issues arise due to the large size of the pills. The purpose of this study was to examine the safety, compliance, and efficacy of Omethyl QTlet soft capsules (OQCs). This multi-center, prospective, observational study evaluated the safety, compliance, and efficacy of OQCs. Patients with hypertriglyceridemia with a history of omega-3 fatty acid intake were enrolled in this study and were prescribed OQCs (2 g−4 g/day) for eight weeks. All adverse events (AEs), adverse drug reactions (ADRs), and serious adverse events (SAEs) were recorded for safety evaluation. Adherence to treatment was assessed using questionnaires, and efficacy was assessed by changes in lipid and lipoprotein levels after eight weeks from baseline. The convenience of taking medication was analyzed for 580 patients, and the efficacy test was performed for 563 patients. The AE and ADR rates were 8.2% and 5.7%, respectively. There were only two SAEs. Of the patients, 55.8% responded that the OQC improved medication convenience, and mean changes in TG, total cholesterol, LDL-C, and non-HDL-C from baseline to eight weeks were −37.88 mg/dL, −11.56 mg/dL, −5.55 mg/dL, and −10.87 mg/dL, respectively (p-values < 0.001). In patients who had previously taken omega-3 fatty acids, OQCs showed safety and efficacy in lowering TG, and it was confirmed that compliance with medicine also improved compared to omega-3 fatty acids.